Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H16N2O8 |
| Molecular Weight | 292.2426 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CC(O)=O
InChI
InChIKey=KCXVZYZYPLLWCC-UHFFFAOYSA-N
InChI=1S/C10H16N2O8/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20)
| Molecular Formula | C10H16N2O8 |
| Molecular Weight | 292.2426 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.webmd.com/balance/tc/chelation-therapy-topic-overview#1 | https://www.empowerpharmacy.com/drugs/edetate-disodium-injection.htmlhttp://umm.edu/health/medical/altmed/supplement/ethylenediaminetetraacetic-acidCurator's Comment: description was created based on several sources, including, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5508a3.htm
Sources: https://www.webmd.com/balance/tc/chelation-therapy-topic-overview#1 | https://www.empowerpharmacy.com/drugs/edetate-disodium-injection.htmlhttp://umm.edu/health/medical/altmed/supplement/ethylenediaminetetraacetic-acid
Curator's Comment: description was created based on several sources, including, http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5508a3.htm
Edetic acid (EDTA) is a chelating agent. The U.S. Food and Drug Administration (FDA) approved edetic acid chelation therapy as a treatment for lead and heavy metal poisoning. Edetic acid in form of disodium salt was withdrawn from the market due to death resulting from hypocalcemia during chelation.
Originator
Sources: https://www.researchgate.net/publication/321552574_Ferdinand_Munz_EDTA_and_40_years_of_inventionshttps://www.google.com/patents/US2130505
Curator's Comment: Edetic acid was synthesized by Ferdinand Munz.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: divalent and trivalent metals |
|||
Target ID: CHEMBL2364029 |
18.3 null [pKd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Calcium disodium versenate Approved UseEdetate calcium disodium is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. Launch Date-5.19523205E11 |
|||
| Curative | Calcium Disodium Versenate Approved UseEdetate calcium disodium is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. Launch Date-5.19523205E11 |
|||
| Curative | Unknown Approved UseUnknown |
|||
| Curative | Unknown Approved UseUnknown |
|||
| Diagnostic | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
51 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3096624 |
1 g single, intramuscular dose: 1 g route of administration: Intramuscular experiment type: SINGLE co-administered: |
EDETATE CALCIUM DISODIUM serum | Homo sapiens population: UNKNOWN age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
60 min |
unknown, unknown |
EDETATE CALCIUM DISODIUM plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
25 mg/kg 2 times / day multiple, intravenous Recommended Dose: 25 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 25 mg/kg, 2 times / day Co-administed with:: 2,3-dimercapto-1-propanol, i.v(3 mg/kg; 6/day; 5 days) Sources: |
unhealthy, 1-8 n = 130 Health Status: unhealthy Condition: Plumbism Age Group: 1-8 Sex: M+F Population Size: 130 Sources: |
Disc. AE: Acute renal failure... Other AEs: Nephrotoxicity... AEs leading to discontinuation/dose reduction: Acute renal failure (3%) Other AEs:Nephrotoxicity (mild, 13%) Sources: |
160 mg/kg single, intravenous Studied dose Dose: 160 mg/kg Route: intravenous Route: single Dose: 160 mg/kg Sources: Page: p.361 |
unhealthy, 49 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Multiple myeloma Age Group: 49 Sex: F Population Size: 1 Sources: Page: p.361 |
Disc. AE: Hypocalcemia... AEs leading to discontinuation/dose reduction: Hypocalcemia Sources: Page: p.361 |
400 mg/kg 1 times / day multiple, intravenous (max) Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: Page: p.360 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Breast cancer Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.360 |
Disc. AE: Restlessness, Hypocalcemia... AEs leading to discontinuation/dose reduction: Restlessness Sources: Page: p.360Hypocalcemia |
400 mg/kg 1 times / day multiple, intravenous (max) Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: Page: p.360 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Breast cancer Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.360 |
Disc. AE: Headache... AEs leading to discontinuation/dose reduction: Headache Sources: Page: p.360 |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Acute renal failure | 3% Disc. AE |
25 mg/kg 2 times / day multiple, intravenous Recommended Dose: 25 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 25 mg/kg, 2 times / day Co-administed with:: 2,3-dimercapto-1-propanol, i.v(3 mg/kg; 6/day; 5 days) Sources: |
unhealthy, 1-8 n = 130 Health Status: unhealthy Condition: Plumbism Age Group: 1-8 Sex: M+F Population Size: 130 Sources: |
| Nephrotoxicity | mild, 13% | 25 mg/kg 2 times / day multiple, intravenous Recommended Dose: 25 mg/kg, 2 times / day Route: intravenous Route: multiple Dose: 25 mg/kg, 2 times / day Co-administed with:: 2,3-dimercapto-1-propanol, i.v(3 mg/kg; 6/day; 5 days) Sources: |
unhealthy, 1-8 n = 130 Health Status: unhealthy Condition: Plumbism Age Group: 1-8 Sex: M+F Population Size: 130 Sources: |
| Hypocalcemia | Disc. AE | 160 mg/kg single, intravenous Studied dose Dose: 160 mg/kg Route: intravenous Route: single Dose: 160 mg/kg Sources: Page: p.361 |
unhealthy, 49 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Multiple myeloma Age Group: 49 Sex: F Population Size: 1 Sources: Page: p.361 |
| Hypocalcemia | Disc. AE | 400 mg/kg 1 times / day multiple, intravenous (max) Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: Page: p.360 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Breast cancer Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.360 |
| Restlessness | Disc. AE | 400 mg/kg 1 times / day multiple, intravenous (max) Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: Page: p.360 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Breast cancer Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.360 |
| Headache | Disc. AE | 400 mg/kg 1 times / day multiple, intravenous (max) Highest studied dose Dose: 400 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg/kg, 1 times / day Sources: Page: p.360 |
unhealthy, 58 n = 1 Health Status: unhealthy Condition: Hypercalcemia|Breast cancer Age Group: 58 Sex: F Population Size: 1 Sources: Page: p.360 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Evaluation of copper availability to plants in copper-contaminated vineyard soils. | 2001 |
|
| Isolation and characterization of rheumatoid arthritis synovial fibroblasts from primary culture--primary culture cells markedly differ from fourth-passage cells. | 2001 |
|
| Brain dystrophin-glycoprotein complex: persistent expression of beta-dystroglycan, impaired oligomerization of Dp71 and up-regulation of utrophins in animal models of muscular dystrophy. | 2001 |
|
| Chemical speciation used to assess [S,S']-ethylenediaminedisuccinic acid (EDDS) as a readily-biodegradable replacement for EDTA in radiochemical decontamination formulations. | 2001 Apr |
|
| Cloning and biochemical characterization of BglC, a beta-glucosidase from the cellulolytic actinomycete Thermobifida fusca. | 2001 Apr |
|
| Reversible inhibition of protein splicing by zinc ion. | 2001 Apr 6 |
|
| Fructose-6-phosphate aldolase is a novel class I aldolase from Escherichia coli and is related to a novel group of bacterial transaldolases. | 2001 Apr 6 |
|
| Characterization of a protease responsible for truncated actin increase in neutrophils of patients with Behçet's disease. | 2001 Feb |
|
| Binding sites for progastrin-derived peptides in colonic crypts. | 2001 Feb |
|
| Estimation of glomerular filtration rate in cancer patients. | 2001 Feb |
|
| Determination of glomerular filtration rate per unit renal volume using computerized tomography: correlation with conventional measures of total and divided renal function. | 2001 Feb |
|
| A high signal-to-noise Ca(2+) probe composed of a single green fluorescent protein. | 2001 Feb |
|
| Urea is a product of ureidoglycolate degradation in chickpea. Purification and characterization of the ureidoglycolate urea-lyase. | 2001 Feb |
|
| Ethylenediamine-N,N,N',N'-tetraacetic acid induces parthenogenetic activation of porcine oocytes at the germinal vesicle stage, leading to formation of blastocysts. | 2001 Feb |
|
| Comparative effects of metal chelating agents on the neuronal cytotoxicity induced by copper (Cu+2), iron (Fe+3) and zinc in the hippocampus. | 2001 Feb 16 |
|
| Role of copper ions and cytochrome P450 in the vasodilator actions of the nitroxyl anion generator, Angeli's salt, on rat aorta. | 2001 Feb 2 |
|
| Robustness of slope-intercept versus slope-only for measurement of glomerular filtration rate. | 2001 Jan |
|
| Phagocytic response of bovine polymorphonuclear leukocytes to different incubation conditions and following exposure to some effectors of phagocytosis and different anticoagulants in vitro. | 2001 Jan |
|
| Enhancement of jejunal absorption of conjugated bile acid by neurotensin in rats. | 2001 Jan |
|
| Use of an orally administered combined sugar solution to evaluate intestinal absorption and permeability in cats. | 2001 Jan |
|
| Flow cytometric analysis of the human articular chondrocyte phenotype in vitro. | 2001 Jan |
|
| Comparison of lateral condensation and thermomechanically compacted warm alpha-phase gutta-percha with a single cone for obturating curved root canals. | 2001 Jan |
|
| Poorly controlled hypertension in a painter with chronic lead toxicity. | 2001 Jan |
|
| Production, purification, and properties of an endoglucanase produced by the hyphomycete Chalara (Syn. Thielaviopsis) paradoxa CH32. | 2001 Jan |
|
| Electron microscopic investigation of the morphology and calcium-induced fusion of lipid vesicles with an oligomerised inner leaflet. | 2001 Jan |
|
| Technical report: lymph node enhancement at MRI with MnDPDP in primary hepatic carcinoma. | 2001 Jan |
|
| Molecular cloning and expression of an alpha-mannosidase gene in Mycobacterium tuberculosis. | 2001 Jan |
|
| Statistical process monitoring of WBC-reduced blood components assessed by two types of software. | 2001 Jan |
|
| Environmental fate and microbial degradation of aminopolycarboxylic acids. | 2001 Jan |
|
| Decreased in situ insulin receptor dephosphorylation in hyperglycemia-induced insulin resistance in rat adipocytes. | 2001 Jan |
|
| Pretreatment of whole blood for use in immunochromatographic assays for hepatitis B virus surface antigen. | 2001 Jan |
|
| Inhibition of CaT1 channel activity by a noncompetitive IP3 antagonist. | 2001 Jan 12 |
|
| Long-term preservation of chilled canine semen: effect of commercial and laboratory prepared extenders. | 2001 Jan 15 |
|
| Expression and enzymatic activity of human disintegrin and metalloproteinase ADAM19/meltrin beta. | 2001 Jan 26 |
|
| Determination of metal complexes of ethylenediaminetetraacetate in the presence of organic matter by high-performance liquid chromatography. | 2001 Jan 5 |
|
| Prevention of the photodamage in the hairless mouse dorsal skin by kojic acid as an iron chelator. | 2001 Jan 5 |
|
| Detection of bile duct leaks using MR cholangiography with mangfodipir trisodium (Teslascan). | 2001 Jan-Feb |
|
| [Plasma homocysteine measurement: a study of pre-analytical variation factors for conditions for total plasma homocysteine concentration]. | 2001 Jan-Feb |
|
| Mechanism of endothelin 1 production in the cochlea of rats. | 2001 Jan-Feb |
|
| Chelating agents. | 2001 Jan-Feb |
|
| Proteolytic action of Bothrops jararaca venom upon its own constituents. | 2001 Jun |
|
| Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. | 2001 Mar |
|
| The CDTA-soluble pectic substances from soybean meal are composed of rhamnogalacturonan and xylogalacturonan but not homogalacturonan. | 2001 Mar |
|
| Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. | 2001 Mar 15 |
|
| Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. | 2001 Mar 30 |
|
| Zinc release from the CH2C6 zinc finger domain of FILAMENTOUS FLOWER protein from Arabidopsis thaliana induces self-assembly. | 2001 Mar 9 |
|
| Deletion of aprA and nprA genes for alkaline protease A and neutral protease A from bacillus thuringiensis: effect on insecticidal crystal proteins. | 2001 Nov 17 |
|
| EDTA redistribution of lead and cadmium into the soft tissues in a human with a high lead burden - should DMSA always be used to follow EDTA in such cases? | 2011 Jun |
Sample Use Guides
hypercalcemia: adults: 50 mg/kg/day (up to 3 g/day) administered by slow IV infusion. Frequency and duration of administration are quite variable, and should be determined based on the patient's serum calcium. Five consecutive daily doses may be administered, followed by 2 days without medication, repeating these courses as necessary to a total of 15 doses.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:35:42 UTC 2023
by
admin
on
Wed Jul 05 22:35:42 UTC 2023
|
| Record UNII |
9G34HU7RV0
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QV03AB03
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
||
|
DSLD |
1018 (Number of products:49)
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
||
|
NDF-RT |
N0000175962
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
||
|
NCI_THESAURUS |
C360
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
||
|
FDA ORPHAN DRUG |
495615
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
||
|
EPA PESTICIDE CODE |
39101
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/16/1668
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
||
|
NDF-RT |
N0000175963
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
||
|
NDF-RT |
N0000175980
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
||
|
NCI_THESAURUS |
C263
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
||
|
WHO-ATC |
V03AB03
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
||
|
CFR |
21 CFR 176.170
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
N0000008556
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY | Decreased Coagulation Factor Activity [PE] | ||
|
M4835
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY | Merck Index | ||
|
6049
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY | |||
|
9G34HU7RV0
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY | |||
|
DB00974
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY | |||
|
60-00-4
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY | |||
|
987
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY | |||
|
1370600
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
ALTERNATIVE | |||
|
42191
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY | |||
|
CHEMBL858
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY | |||
|
1233508
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY | |||
|
Ethylenediaminetetraacetate
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY | |||
|
100000080510
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY | |||
|
534
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY | |||
|
9G34HU7RV0
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY | |||
|
SUB06456MIG
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY | |||
|
C61742
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY | |||
|
D004492
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY | |||
|
3755
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY | |||
|
200-449-4
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY | |||
|
DTXSID6022977
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY | |||
|
809
Created by
admin on Wed Jul 05 22:35:42 UTC 2023 , Edited by admin on Wed Jul 05 22:35:42 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
|
PARENT -> SALT/SOLVATE | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
SOLVATE->ANHYDROUS | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
